SEC Filing Summary

David J Moss, Chief Executive Officer and Director of Inmune Bio, Inc., exercised 9,014 common stock purchase warrants on July 2, 2026. These warrants were part of the April 2024 offerings and were amended on December 22, 2025. The exercise was done for cash at a reduced price of $1.40 per share, resulting in the acquisition of 9,014 shares of common stock. This exercise represents 50% of the warrants held by Mr. Moss. In exchange, the maturity date for the remaining 50% of the warrants was extended from June 30, 2026, to December 31, 2027. Following this transaction, Mr. Moss directly owns 1,294,883 shares of common stock. The original exercise price for the warrants was $0.125 per share, but the inducement letter led to a reduced exercise price of $1.40 for the exercised portion.